Woodmont Investment Counsel LLC Decreases Holdings in Harrow, Inc. (NASDAQ:HROW)

Woodmont Investment Counsel LLC lowered its stake in Harrow, Inc. (NASDAQ:HROW - Free Report) by 60.7% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 80,955 shares of the company's stock after selling 124,908 shares during the quarter. Woodmont Investment Counsel LLC owned 0.23% of Harrow worth $3,640,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of HROW. Hills Bank & Trust Co bought a new position in Harrow in the third quarter worth approximately $107,000. Rice Hall James & Associates LLC raised its position in shares of Harrow by 23.1% during the third quarter. Rice Hall James & Associates LLC now owns 314,881 shares of the company's stock worth $14,157,000 after purchasing an additional 59,019 shares during the period. China Universal Asset Management Co. Ltd. raised its position in shares of Harrow by 64.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 6,825 shares of the company's stock worth $307,000 after purchasing an additional 2,668 shares during the period. Semanteon Capital Management LP bought a new position in shares of Harrow in the 3rd quarter worth $686,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in Harrow by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company's stock valued at $57,000 after purchasing an additional 227 shares during the period. Institutional investors and hedge funds own 72.76% of the company's stock.

Harrow Stock Up 2.8 %

Shares of HROW traded up $1.35 during trading hours on Thursday, reaching $49.59. 297,367 shares of the stock traded hands, compared to its average volume of 494,608. The company has a current ratio of 2.60, a quick ratio of 2.43 and a debt-to-equity ratio of 3.18. The stock has a fifty day simple moving average of $46.70 and a 200 day simple moving average of $30.57. Harrow, Inc. has a 52 week low of $7.60 and a 52 week high of $59.23. The company has a market cap of $1.76 billion, a price-to-earnings ratio of -50.78 and a beta of 0.76.

Harrow (NASDAQ:HROW - Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.12. Harrow had a negative net margin of 21.78% and a negative return on equity of 40.59%. The company had revenue of $48.94 million for the quarter, compared to analyst estimates of $42.78 million. On average, equities analysts forecast that Harrow, Inc. will post 0.09 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on HROW shares. Craig Hallum raised their price objective on shares of Harrow from $45.00 to $65.00 and gave the company a "buy" rating in a research note on Friday, October 4th. B. Riley reaffirmed a "buy" rating and issued a $50.00 price objective on shares of Harrow in a research note on Thursday, August 29th. Finally, Lake Street Capital raised their price objective on shares of Harrow from $45.00 to $55.00 and gave the company a "buy" rating in a research note on Friday, October 4th.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.